Literature DB >> 31933016

Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV.

Dionna W Williams1,2, Yuliang Li3, Yanxun Xu3,4, Leah H Rubin5,6,7, Raha Dastgheyb8, Kathryn C Fitzgerald8, Pauline M Maki9, Amanda B Spence10, Deborah R Gustafson11, Joel Milam12, Anjali Sharma13, Adaora A Adimora14, Igho Ofotokun15, Margaret A Fischl16, Deborah Konkle-Parker17, Kathleen M Weber18.   

Abstract

Antiretroviral therapy (ART) is inconsistently associated with depression. These associations may depend on factors such as biological sex, age, and health status. Identifying such factors may help optimize treatment of HIV and depression. We implemented a novel approach to examine interindividual variability in the association between ART agents and depressive symptoms. 3434 women living with HIV (WLWH) from the Women's Interagency HIV Study (WIHS) were computationally divided into subgroups based on sociodemographic (e.g., age) and longitudinal (from 1995 to 2016) behavioral and clinical profiles (e.g., substance use, HIV RNA, CD4 counts). Five subgroups (n's ranged from 482 to 802) were identified and characterized as those with: controlled HIV/vascular comorbidities; profound HIV legacy effects; younger women [<45 years of age] with hepatitis C; primarily 35-55 year olds; and poorly controlled HIV/substance use. Within each subgroup, we examined associations between ART agents used over the past 6 months and item-level depressive symptoms on the Center for Epidemiologic Studies Depression Scale. Tenofovir (4 of 5 subgroups) followed by efavirenz, emtricitabine, stavudine, lopinavir, etravirine, nelfinavir, ritonavir, and maraviroc were the most common agents associated with depressive symptoms, although the pattern and directionality varied by subgroup. For example, lopinavir was associated with fewer symptoms among the subgroup with a legacy HIV effect but more symptoms among the subgroup with well-controlled HIV/vascular comorbidities. Unexpectedly, dolutegravir and raltegravir were not associated with depressive symptoms among any subgroup. Findings underscore marked interindividual variability in ART agents on depression in WLWH. Sociodemographic, clinical, and behavioral factors are important determinants of the relationship between ART agents and depressive symptoms in WLWH. Graphical Abstract Are antiretroviral agents a risk factor for depressive symptoms in women with HIV? We examined associations between ART-agents and depressive symptoms among similar subgroups of women with HIV from the Women's Interagency HIV Study. The patterns of associations depended on sociodemographic, clinical, and behavioral characteristics of women.

Entities:  

Keywords:  Antiretrovirals; Depression; HIV; Heterogeneity; Women

Mesh:

Substances:

Year:  2020        PMID: 31933016      PMCID: PMC7430262          DOI: 10.1007/s11481-019-09899-2

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   7.285


  58 in total

Review 1.  The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench.

Authors:  Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

2.  Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.

Authors:  Alberto Borghetti; Gianmaria Baldin; Amedeo Capetti; Gaetana Sterrantino; Stefano Rusconi; Alessandra Latini; Andrea Giacometti; Giordano Madeddu; Chiara Picarelli; Ramona De Marco; Maria V Cossu; Filippo Lagi; Roberto Cauda; Andrea De Luca; Simona Di Giambenedetto
Journal:  AIDS       Date:  2017-01-28       Impact factor: 4.177

3.  Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.

Authors:  Brookie M Best; Scott L Letendre; Peter Koopmans; Steven S Rossi; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina M Marra; Justin C McArthur; J Allen McCutchan; Susan Morgello; David M Simpson; Edmund V Capparelli; Ronald J Ellis; Igor Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

4.  Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial.

Authors:  Alejandro Arenas-Pinto; Birgit Grund; Shweta Sharma; Esteban Martinez; Nathan Cummins; Julie Fox; Karin L Klingman; Dalibor Sedlacek; Simon Collins; Patricia M Flynn; William M Chasanov; Eynat Kedem; Christine Katlama; Juan Sierra-Madero; Claudia Afonso; Pim Brouwers; David A Cooper
Journal:  Clin Infect Dis       Date:  2018-07-18       Impact factor: 9.079

5.  The Relationship Between Efavirenz as Initial Antiretroviral Therapy and Suicidal Thoughts Among HIV-Infected Adults in Routine Care.

Authors:  Angela M Bengtson; Brian W Pence; Katie R Mollan; Jessie K Edwards; Richard D Moore; Conall OʼCleirigh; Ellen F Eaton; Joseph J Eron; Mari M Kitahata; William C Mathews; Heidi Crane; Michael J Mugavero
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-01       Impact factor: 3.731

6.  The Women's Interagency HIV Study. WIHS Collaborative Study Group.

Authors:  S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman
Journal:  Epidemiology       Date:  1998-03       Impact factor: 4.822

Review 7.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

8.  Cohort Profile: The Women's Interagency HIV Study (WIHS).

Authors:  Adaora A Adimora; Catalina Ramirez; Lorie Benning; Ruth M Greenblatt; Mirjam-Colette Kempf; Phyllis C Tien; Seble G Kassaye; Kathryn Anastos; Mardge Cohen; Howard Minkoff; Gina Wingood; Igho Ofotokun; Margaret A Fischl; Stephen Gange
Journal:  Int J Epidemiol       Date:  2018-04-01       Impact factor: 7.196

9.  The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses.

Authors:  Christy Anthonypillai; Julie E Gibbs; Sarah A Thomas
Journal:  Cerebrospinal Fluid Res       Date:  2006-01-03

10.  Neural correlates of somatoform disorders from a meta-analytic perspective on neuroimaging studies.

Authors:  Markus Boeckle; Marlene Schrimpf; Gregor Liegl; Christoph Pieh
Journal:  Neuroimage Clin       Date:  2016-04-10       Impact factor: 4.881

View more
  7 in total

1.  BAGEL: A BAYESIAN GRAPHICAL MODEL FOR INFERRING DRUG EFFECT LONGITUDINALLY ON DEPRESSION IN PEOPLE WITH HIV.

Authors:  Yuliang Li; Yang Ni; Leah H Rubin; Amanda B Spence; Yanxun Xu
Journal:  Ann Appl Stat       Date:  2022-03-28       Impact factor: 1.959

Review 2.  Neuroinflammation in HIV-associated depression: evidence and future perspectives.

Authors:  Arish Mudra Rakshasa-Loots; Heather C Whalley; Jaime H Vera; Simon R Cox
Journal:  Mol Psychiatry       Date:  2022-05-26       Impact factor: 13.437

3.  Integrase Inhibitors are Associated with Neuropsychiatric Symptoms in Women with HIV.

Authors:  Leah H Rubin; Jane A O'Halloran; Dionna W Williams; Yuliang Li; Kathryn C Fitzgerald; Raha Dastgheyb; Alexandra L Damron; Pauline M Maki; Amanda B Spence; Anjali Sharma; Deborah R Gustafson; Joel Milam; Kathleen M Weber; Adaora A Adimora; Igho Ofotokun; Margaret A Fischl; Deborah Konkle-Parker; Yanxun Xu
Journal:  J Neuroimmune Pharmacol       Date:  2022-02-17       Impact factor: 7.285

Review 4.  HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis.

Authors:  Nontokozo D Matume; Denis M Tebit; Pascal O Bessong
Journal:  AIDS Res Ther       Date:  2020-02-07       Impact factor: 2.250

Review 5.  How Does COVID-19 Affect the Neurobiology of Suicide?

Authors:  I Conejero; B Nobile; E Olié; Ph Courtet
Journal:  Curr Psychiatry Rep       Date:  2021-03-03       Impact factor: 5.285

Review 6.  Pitfalls of Antiretroviral Therapy: Current Status and Long-Term CNS Toxicity.

Authors:  Harrison Rudd; Michal Toborek
Journal:  Biomolecules       Date:  2022-06-26

7.  Improvement in depressive symptoms after antiretroviral therapy initiation in people with HIV in Rakai, Uganda.

Authors:  Noeline Nakasujja; Alyssa C Vecchio; Deanna Saylor; Sarah Lofgren; Gertrude Nakigozi; David R Boulware; Alice Kisakye; James Batte; Richard Mayanja; Aggrey Anok; Steven J Reynolds; Thomas C Quinn; Carlos A Pardo; Anupama Kumar; Ronald H Gray; Maria J Wawer; Ned Sacktor; Leah H Rubin
Journal:  J Neurovirol       Date:  2021-07-31       Impact factor: 3.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.